ABIO
Income statement / Annual
Last year (2023), ARCA biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, ARCA biopharma, Inc.'s net income was -$5.34 M.
See ARCA biopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$111,000.00 |
$114,000.00 |
$91,000.00 |
$93,000.00 |
$89,000.00 |
$22,000.00 |
$27,000.00 |
$24,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$111,000.00 |
-$114,000.00 |
-$91,000.00 |
-$93,000.00 |
-$89,000.00 |
-$22,000.00 |
-$27,000.00 |
-$24,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$1.01 M
|
$4.75 M
|
$13.83 M
|
$4.99 M
|
$1.83 M
|
$4.24 M
|
$14.08 M
|
$12.35 M
|
$7.06 M
|
$5.63 M
|
| General & Administrative
Expenses |
$6.28 M
|
$5.85 M
|
$5.50 M
|
$4.77 M
|
$3.98 M
|
$3.88 M
|
$4.64 M
|
$4.27 M
|
$4.39 M
|
$4.07 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.28 M
|
$5.85 M
|
$5.50 M
|
$4.77 M
|
$3.98 M
|
$3.88 M
|
$4.64 M
|
$4.27 M
|
$4.39 M
|
$4.07 M
|
| Other Expenses |
$0.00 |
-$5,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$7.30 M |
$10.60 M |
$19.34 M |
$9.77 M |
$5.81 M |
$8.12 M |
$18.71 M |
$16.61 M |
$11.46 M |
$9.69 M |
| Cost And Expenses |
$7.30 M |
$10.60 M |
$19.34 M |
$9.77 M |
$5.81 M |
$8.12 M |
$18.71 M |
$16.61 M |
$11.46 M |
$9.69 M |
| Interest Income |
$1.96 M |
$675,000.00 |
$13,000.00 |
$28,000.00 |
$172,000.00 |
$162,000.00 |
$167,000.00 |
$169,000.00 |
$14,000.00 |
$7,000.00 |
| Interest Expense |
$0.00 |
$675,000.00 |
$0.00 |
$9,000.00 |
$7,000.00 |
$8,000.00 |
$6,000.00 |
$0.00 |
$4,000.00 |
$3,000.00 |
| Depreciation &
Amortization |
$111,000.00
|
$114,000.00
|
$91,000.00
|
$93,000.00
|
$89,000.00
|
$22,000.00
|
$27,000.00
|
$24,000.00
|
$19,000.00
|
$12,000.00
|
| EBITDA |
-$7.30 M
|
-$10.60 M
|
-$19.32 M
|
-$9.74 M
|
-$5.55 M
|
-$7.93 M
|
-$18.55 M
|
-$16.12 M
|
-$11.42 M
|
-$9.67 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.96 M
|
$670,000.00
|
$13,000.00
|
$19,000.00
|
$165,000.00
|
$154,000.00
|
$161,000.00
|
$169,000.00
|
$10,000.00
|
$4,000.00
|
| Income Before Tax |
-$5.34 M |
-$9.93 M |
-$19.32 M |
-$9.75 M |
-$5.65 M |
-$7.96 M |
-$18.55 M |
-$16.44 M |
-$11.45 M |
-$9.69 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$111,000.00 |
-$670,000.00 |
-$91,000.00 |
-$9,000.00 |
-$167,000.00 |
-$31,000.00 |
-$61,000.00 |
$188,000.00 |
$14,000.00 |
$7,000.00 |
| Net Income |
-$5.34 M |
-$9.26 M |
-$19.23 M |
-$9.74 M |
-$5.48 M |
-$7.93 M |
-$18.49 M |
-$16.46 M |
-$11.45 M |
-$9.69 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.37 |
-0.64 |
-1.38 |
-2.07 |
-4.15 |
-10.31 |
-31.91 |
-32.68 |
-32.76 |
-59.55 |
| EPS Diluted |
-0.37 |
-0.64 |
-1.38 |
-2.07 |
-4.15 |
-10.31 |
-31.91 |
-32.68 |
-32.76 |
-59.55 |
| Weighted Average Shares
Out |
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$1.32 M
|
$769,392.00
|
$579,521.00
|
$503,746.00
|
$349,408.00
|
$162,709.00
|
| Weighted Average Shares
Out Diluted |
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$1.32 M
|
$769,398.00
|
$579,526.00
|
$503,750.00
|
$349,408.00
|
$162,709.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
